NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody-drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor-based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest that the addition of CD3 × CD20 bispecific antibodies to chemoimmunotherapy improves outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, MCL, and DLBCL.
Authors
- Jeremy S. Abramson (ORCID: https://orcid.org/0000-0001-8467-9257)
- Chris R. Kelsey (ORCID: https://orcid.org/0000-0002-4961-8982)
- Justin Paul Kline (ORCID: https://orcid.org/0000-0002-2967-6448)
- Leo I. Gordon (ORCID: https://orcid.org/0000-0003-1666-7064)
- Rebecca L. King (ORCID: https://orcid.org/0000-0002-7132-0226)
- Paolo F. Caimi (ORCID: https://orcid.org/0000-0003-1436-0464)
- Boyu Hu (ORCID: https://orcid.org/0000-0001-9848-9497)
- Thomas Matthew Habermann (ORCID: https://orcid.org/0000-0003-3532-9132)
- Luis Fayad (ORCID: https://orcid.org/0000-0002-1844-5548)
- Julie Chang (ORCID: https://orcid.org/0000-0002-1255-1163)
- Rachel Rabinovitch (ORCID: https://orcid.org/0000-0002-6016-2226)
- Susan Krivacic
- Erin Reid (ORCID: https://orcid.org/0000-0003-4029-8641)
- Megan S. Lim (ORCID: https://orcid.org/0000-0002-0415-2867)
- Daniel J. Landsburg (ORCID: https://orcid.org/0000-0002-5077-4181)
- Praveen Ramakrishnan (ORCID: https://orcid.org/0000-0003-4644-1189)
- Yasmin H. Karimi (ORCID: https://orcid.org/0000-0003-2648-4448)
- Joseph M. Tuscano (ORCID: https://orcid.org/0000-0002-0522-1406)
- Hayder Saeed (ORCID: https://orcid.org/0000-0001-5295-6088)
- Kenneth B. Roberts (ORCID: https://orcid.org/0000-0003-0063-0021)
- Marcus Messmer (ORCID: https://orcid.org/0000-0002-8030-1190)
- Bhagirathbhai Dholaria (ORCID: https://orcid.org/0000-0003-2371-3655)
- Ranjana H. Advani (ORCID: https://orcid.org/0000-0002-3219-2292)
- B. Andreadis
- Andrew David Zelenetz (ORCID: https://orcid.org/0000-0003-1403-6883)
- Francisco J. Hernandez‐Ilizaliturri (ORCID: https://orcid.org/0000-0001-8054-3539)
- Naoyuki G. Saito (ORCID: https://orcid.org/0000-0001-9331-9982)
- Nancy L. Bartlett (ORCID: https://orcid.org/0000-0001-8470-394X)
- Julie M. Vose (ORCID: https://orcid.org/0000-0003-1015-7434)
- Lihua E. Budde (ORCID: https://orcid.org/0000-0003-1464-5494)
- Hema Sundar
- Ann Steward LaCasce (ORCID: https://orcid.org/0000-0001-7349-0176)
- Stephen D. Smith (ORCID: https://orcid.org/0000-0001-5354-7593)
- Muhammad Saad Hamid (ORCID: https://orcid.org/0000-0002-2321-1885)
- Beth Christian
- Mary A. Dwyer
- Sven deVos
- Lode J. Swinnen
Institutions
- Fox Chase Cancer Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Barnes-Jewish Hospital (US)
- City Of Hope National Medical Center (US)
- St. Jude Children's Research Hospital (US)
- Cleveland Clinic (US)
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Tennessee Health Science Center (US)
- Breast Cancer Research Foundation (US)
- University of Utah (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- UC San Diego Health System (US)
- Huntsman Cancer Institute (US)
- Cancer Institute (WIA) (IN)
- Susan Thompson Buffett Foundation (US)
- WinnMed (US)
- Yale Cancer Center (US)
- Moffitt Cancer Center (US)
- Massachusetts General Hospital (US)
- Fred Hutch Cancer Center (US)
- Southwestern Medical Center (US)
- Jewish Hospital (US)
- University of Wisconsin Carbone Cancer Center (US)
- Sidney Kimmel Cancer Center (US)
- University Hospitals Seidman Cancer Center (US)
- Duke Medical Center (US)
- University of Colorado Cancer Center (US)
- Dana-Farber Brigham Cancer Center (US)
- Smilow Cancer Hospital (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
- Moores Cancer Center
- University of Chicago Medicine Comprehensive Cancer Center
- UCLA Jonsson Comprehensive Cancer Center
- Vanderbilt-Ingram Cancer Center
- Stanford Cancer Institute
- Duke Cancer Institute
- Fred and Pamela Buffett Cancer Center
- UC Davis Comprehensive Cancer Center
- Harold C. Simmons Comprehensive Cancer Center
- National Comprehensive Cancer Network
- Marymount University (US)
- Indiana University (US)
- University of Pennsylvania (US)
- University of California, Davis (US)
- The University of Texas Southwestern Medical Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-10-01
- DOI
- https://doi.org/10.6004/jnccn.2025.0048
- Citations
- 4
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.89